We believe that, even though this study highlights new elements concerning the safety of sentinel node biopsy during pregnancy, it overestimates the rationale for doing so and does not provide enough elements justifying sentinel node biopsy in pregnant breast cancer patients outside of a clinical trial. We evaluated in our institution's series whether the characteristics of patients diagnosed with breast cancer during pregnancy meet those considered classically compatible with a sentinel lymph node procedure (T1 breast carcinoma without clinical axillary nodal involvement [3]). Among 44 patients with breast cancer during pregnancy treated in our institution between 1996 and 2004, tumour sizes ranged from 8 to 200 mm (mean 39.8 mm) and only 28% had T1 tumours, as shown in previous reports. Furthermore, 26 patients out of 44 were classified N1 or N2 at the final pathologic examination (59%) [3
]. In the literature series, the same results have been observed: 60% of pregnant patients with breast cancer have a pathological nodal involvement [4
]. Furthermore, in our series, 5 of 11 (45%) patients with T1/pT1 confirmed tumours were node-positive. Our data confirm that pregnant breast cancer patients theoretically eligible for SLN are infrequent and that even among these patients, the nodal involvement rate is high. Beside this, another main concern regarding the use of SLN during pregnancy is that breast modifications occurring during pregnancy may modify tracer migration properties. This issue was not discussed by Gentilini et al. [1
]. Whether lymphatic pathways are altered in pregnancy is unknown. No data are currently available to confirm or disprove this hypothesis.
We therefore think that pregnant breast cancer patients should not currently undergo a sentinel node biopsy without axillary dissection outside of a clinical trial.
1 Departments of Surgery, 2 Oncology, Institut Gustave Roussy, Villejuif, France
* Email: gil.dubernard{at}tnn.ap-hop-paris.fr
References
1. Gentilini O, Cremonesi M, Trifiro G et al. Safety of sentinel node biopsy in pregnant patients with breast cancer. Ann Oncol 2004; 15: 13481351.
2. Schwartz GF, Hortobagyi GN. Consensus Conference Committee. Proceedings of the Consensus Conference on Neoadjuvant Chemotherapy in Carcinoma of the Breast, April 2628, 2003, Philadelphia, PA. Breast J 2004; 10: 273294.[CrossRef]
3. Schwartz GF, Giuliano AE, Veronesi U. Proceedings of the Consensus Conference on the Role of Sentinel Lymph Node Biopsy in Carcinoma of the Breast, April 1922, 2001, Philadelphia, PA. Cancer 2002; 94: 25422551.[CrossRef][ISI][Medline]
4. Woo JC, Yu T, Hurd TC. Breast cancer in pregnancy: a literature review. Arch Surg 2003; 138: 9198 (Discussion p. 99).
|